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Abstract
The purpose of the present study was to investigate whether cilostazol, a phosphodiesterase-III inhibitor and antiplatelet
drug, would prevent tPA-associated hemorrhagic transformation. Mice subjected to 6-h middle cerebral artery occlusion
were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h. We used
multiple imaging (electron microscopy, spectroscopy), histological and neurobehavioral measures to assess the effects of
the treatment at 18 h and 7 days after the reperfusion. To further investigate the mechanism of cilostazol to beneficial
effect, we also performed an in vitro study with tPA and a phosphodiesterase-III inhibitor in human brain microvascular
endothelial cells, pericytes, and astrocytes. Combination therapy with tPA plus cilostazol prevented development of
hemorrhagic transformation, reduced brain edema, prevented endothelial injury via reduction MMP-9 activity, and
prevented the blood-brain barrier opening by inhibiting decreased claudin-5 expression. These changes significantly
reduced the morbidity and mortality at 18 h and 7 days after the reperfusion. Also, the administration of both drugs
prevented injury to brain human endothelial cells and human brain pericytes. The present study indicates that a
phosphodiesterase-III inhibitor prevents the hemorrhagic transformation induced by focal cerebral ischemia in mice treated
with tPA.
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Introduction
Accumulating evidence suggests that, for acute ischemic brain
attack, it is a fact that thrombolysis is beneficial for patients with an
ischemic stroke if given during the first 4.5 h of symptoms
(NINDS, ECASS III) [1,2]. Beyond this time window, delayed
tissue plasminogen activator (tPA) does not appear to be as
beneficial and actually increases the risk of serious side effects.
Conditionally, delayed thrombolysis may be related to increased
risk of brain edema and hemorrhagic transformation and other
potential side effects [3]. Therefore, any way to reduce tPA-
associated blood-brain barrier (BBB) injury may extend the time
window for safe and effective reperfusion therapy, and ultimately
increase the overall efficacy of tPA thrombolytic therapy.
Cilostazol, a selective inhibitor of phosphodiesterase III, is an
antiplatelet drug and a vasodilator via an increased cyclic AMP
(cAMP) level and cyclic GMP level [4,5]. Cilostazol has been
approved and used as a vasodilating antiplatelet drug for the
treatment of ischemic symptoms in chronic peripheral arterial
obstruction or intermittent claudication and for secondary
prevention of cerebral infarction (CSPS I) [6]. Cilostazol has also
been used after aneurismal SAH to prevent development of
delayed cerebral vasospasm [7]. Recently, cilostazol has been
shown to be a more effective and safer alternative to aspirin for
long-term prevention of the recurrence of ischemic stroke in
patients with chronic ischemic stroke [8].
On the other hand, researchers have reported that cilostazol has
a neuroprotective effect against ischemic brain injury and prevents
attenuated acute brain infarction induced by middle cerebral
artery (MCA) occlusion (MCAO) and reperfusion in rats [9-10],
which suggests that cilostazol has the potential to ameliorate acute
ischemic stroke by minimizing evolving ischemic injury. We
further reported that cilostazol protects against hemorrhagic
transformation in mice transient focal cerebral ischemia [11]
and combination treatment with normobaric hyperoxia, cilostazol
protects mice against focal cerebral ischemia [12], and cilostazol
provided neuroprotection against filamental MCAO-mediated
increases in metallothionein-1 and -2 [13]. In addition, increasing
evidence indicates that cilostazol may offer endothelial protection
via both an inhibition of lipopolysaccharide-induced apoptosis and
an inhibition of neutrophil adhesion to endothelial cells [14]. Since
endothelium is one of the main constituents of BBB, cilostazol may
provide not only endothelial protection but also BBB protection.
The above suggests that cilostazol may not only be neuroprotec-
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by tPA during reperfusion after ischemia. By so doing, cilostazol
may extend the therapeutic time window for thrombolytic
treatment. Very recently, cilostazol has been reported to be more
effective than aspirin in the secondary prevention of all types of
stroke in patients and, in particular, prevent the secondary attack
of hemorrhagic stroke in patients (CSPS II) [15]. Indeed, a
characteristic feature of cilostazol is that it has weaker hemor-
rhagic side effects than other antiplatelet drugs and does not
increase the bleeding time [16]. Accordingly, the aim of this study
was to assess whether tPA-induced hemorrhagic transformation is
indeed suppressed by acute cilostazol treatment in an MCAO
model and observe an electron microscopic view of microvessels to
elucidate the mechanism underlying tPA-induced hemorrhagic
transformation.
Results
Cerebral Infarction and Hemorrhagic Transformation
Induced by tPA
Early tPA treatment at 2 or 3 h significantly reduced infarct
areas and volumes at 24 h after MCAO, but no efficacy was
obtained with the delayed 6-h tPA administration (Fig. 1A–C).
Instead, delayed tPA treatments induced detectable amounts of
hemorrhagic transformation in the ischemic brain (Fig. 1D).
Combination therapy with 6-h tPA plus cilostazol did not improve
the infarct areas (data not shown) or volumes (Fig. 2A) after
delayed tPA at 6 h, but improved the hemorrhagic transformation
(Fig. 2B and 2C). No mice had died at 24 h after 2 h and 3 h
MCAO in the vehicle and tPA groups.
Neurological Function Induced by tPA
The ischemic mice showed apparent neurological deficits just
after and at 18 h after reperfusion.
There was no significant difference in the neurological deficit
score among the three groups just after reperfusion. In contrast, at
18 h after reperfusion, the combination group exhibited a
significantly reduced mortality rate and prevented worsening of
the neurological deficit scores (Fig. 2D and 2E).
Acute BBB Injury, Intracerebral Hemorrhage, Brain
Edema, and MMP-9 Activity Induced by tPA
tPA administered at the delayed 6 h induced significantly the
hemorrhagic transformation at 18 h after reperfusion. The
combination of tPA plus cilostazol at 6 h significantly ameliorated
the severity of hemorrhagic transformation (Fig. 3A). Correspond-
ingly, combination therapy significantly prevented tPA-induced
brain edema at 18 h after reperfusion (Fig. 3B). Our results
demonstrate that cilostazol effectively inhibited tPA-induced
amplification of cerebral hemorrhage and brain edema. The
expression of MMP-9 was remarkably upregulated by tPA (Fig.
3C). The MMP-9 activity was significantly decreased with tPA
plus cilostazol at 6 h. The activity of MMP-9 paralleled the degree
of the hemorrhage volume in the ischemic brain. These findings
suggest that cilostazol suppressed tPA-induced intracerebral
hemorrhage by reducing the activity of MMP-9.
Subacute Brain Injury Induced by tPA
tPA alone significantly decreased mortality at 7 days after
MCAO, but combination therapy with tPA plus cilostazol did not
improve the mortality more than tPA alone (x
2 test, vehicle; n=5/
5, tPA; n=8/13, tPA plus cilostazol; n=9/16). To assess the effect
of cilostazol on subacute brain injury, we used locomotor activity
at 7 days after MCAO. In comparison with the tPA alone group,
the tPA plus cilostazol group showed a significantly lower total
activity count over the first 120 min (Fig. 4A and 4B).
Electron Microscopic Analysis in Endothelial Cells
An electron microscopic examination revealed that the nuclei of
the endothelial cells had disappeared on the ipsilateral side in the
brain tissue treated with tPA alone, though there were nuclei on
the ipsilateral side in the brain tissue treated with vehicle.
Furthermore, delayed tPA at 6 h significantly increased brain
edema around the capillary arteries in the ischemic lesion. In
contrast, combination therapy with tPA plus cilostazol significantly
prevented the disappearance of the nuclei of the endothelial cells
and reduced brain edema induced by tPA (Fig. 5A–F). These
observations indicate that the mechanism of the neurovascular
unit dissociated by tPA involved the injury of endothelial cells,
which was prevented by cilostazol.
Evaluation Claudin-5 Expression with Western Blotting
Analysis
To characterize changes in the tight junction, we also evaluated
the expression of claudin-5 with Western blotting. Interestingly,
delayed tPA at 6 h markedly diminished claudin-5 levels in brain
tissue. In contrast, combination therapy with tPA plus cilostazol at
6 h significantly prevented a decrease in claudin-5 expression (Fig.
5G).
tPA and Cilostazol in Various Cell Cultures
To assess the effects of combination treatment with tPA and
cilostazol on the neurovascular unit, we evaluated the neuronal
damage in endothelial cells, pericytes, and astrocytes. In
endothelial cells, the LDH level was not changed by 3, 10, 30,
and 100 mg/ml of tPA (data not shown) but was increased by 300-
mg/ml tPA, and the increase was significantly reduced by the
combination of 10 to 100 mM of cilostazol in a concentration-
dependent manner (Fig. 6A). On the other hand, in pericytes and
astrocytes, the LDH level was not changed by 3, 10, 30, and
100 mg/ml of tPA (data not shown) but increased by 300-mg/ml
tPA. Furthermore, the increase was significantly reduced by the
combination of 100 mM cilostazol in pericytes but not in astrocytes
(Fig. 6B, C). We next examined the effect of db-cAMP on cell
damage in tPA-treated endothelial cells. db-cAMP at 300 and
1000 mM significantly prevented the cell damage induced by tPA
in a concentration-dependent manner (Fig. 6A). Given the average
plasma concentration of cilostazol orally administered to humans
(100 mg/body/day) is about 2 to 10 mM and may be partially
higher in our body, the concentration of cilostazol we used is
comparable to a clinical concentration [17,18].
Discussion
We have previously reported that cilostazol monotherapy
reduced the infarct volume, hemorrhagic area, and brain edema
in mice subjected to MCA occlusion and reperfusion [11]. In the
present study, we examined whether cilostazol prevented the
hemorrhagic transformation induced by tPA and found that
cilostazol reduced the extent of hemoglobin content, water
content, and MMP-9 activity in mice subjected to MCA occlusion
and reperfusion, supporting the idea that cilostazol limits or
prevents BBB disruption after the ischemic injury.
The tPA-induced breakdown of the barrier permeability of BBB
often accelerates the progression of diseases such as cerebral
ischemia. However, the molecular mechanisms involved with the
barrier disruption by tPA have not been determined completely.
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disruption of endothelial barrier may yield new therapeutic targets
of intractable diseases. Therefore, we focused on claudin-5, which
is a member of the claudin family and is involved in the assembly
of tight junctions between microvascular endothelial cells [19,20].
Our electron microscopic view revealed that the endothelial cells
were severely degraded, the nuclei of the cells had disappeared,
and the inner lumen had become thin in the tPA-treated mice. In
the previous report, tPA increased apoptotic vessels compared to
the vehicle treated mice after ischemia-reperfusion [21]. An
induction of the apoptotic cascade seems to be involved in rtPA
cytotoxicity on human corneal endothelial cells [22]. Therefore,
the disappearance of the nuclei of the endothelial cells with tPA
treatment may be due to apoptosis. With this in vivo model, the
degree of claudin-5 was reduced in the mouse ischemic brain
treated with tPA. Cilostazol prevented a decrease in claudin-5
Figure 1. Effects of tPA on cerebral infarction and hemorrhage at 18 h after reperfusion. TTC-stained coronal sections show infarct tissues
(pale unstained region). Brain sections (from extreme left) were acquired from 2 h vehicle, 3 h vehicle, 6 h vehicle, respectively. They were acquired
from 2 h tPA (left), 3 h tPA, and 6 h tPA, respectively (A). These figures show the effects of tPA on the cerebral infarct area (B), volume (C), and
hemorrhage area (D). tPA at 2 h and 3 h significantly decreased the infarct area and volume. Delayed tPA at 6 h had no effect on infarction but
induced cerebral hemorrhage. *P,0.05 vs. vehicle (Welch’s t test, n=5–8). Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0015178.g001
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observed in electron microscopic views of the mice treated with
tPA and tPA plus cilostazol. Our results showed that the
expression of claudin-5 was altered by tPA, which results in the
disruption of the barrier permeability of neural vascular
endothelial cells, and whose disruption was prevented by
cilostazol. Previous study suggested that the cause of BBB
disruption is because of a proteolytic degradation of the vascular
membrane in cerebral ischemia [23]. Among proteases, matrix
metalloproteinases (MMP), in particular MMP-2 and MMP-9, are
able to digest the endothelial basal lamina and therefore may play
a pivotal role in promoting BBB permeability [24]. Accumulating
evidence suggests that MMP-9 activation is closely related to those
side effects of t-PA [25]. Jin et al. have reported that loss of
claudin-5 signals appears to be ameliorated in CD47 knockout
mice and the genetic deletion of CD47 reduces MMP-9 expression
[26]. Taken together, in the present study, cilostazol could be used
to upregulate claudin-5 and downregulate the overall inflamma-
tory MMP-9 responses.
The concept of the ‘‘neurovascular unit’’ has emerged as a new
paradigm for understanding the pathology of CNS diseases,
including stroke, in recent years [27]. In order to truly preserve
brain tissue and function, one may have to conserve all the
complex signals and interactions between a network of multiple
cell types, including neurons, astrocytes, and microvascular
endothelial cells. Therefore, we examined the effects of cilostazol
on tPA-induced cell damage in human brain microvascular
endothelial cells, pericytes, and astrocytes. tPA at a concentration
Figure 2. Effects of tPA and cilostazol on cerebral infarction and hemorrhage at 18 h after reperfusion. The other figures show the
effects of tPA and cilostazol regarding the cerebral infarct volume (A) and hemorrhage area (B). Combination therapy with tPA plus cilostazol at 6 h
had no effect on infarction but prevented hemorrhage. *P,0.01 vs. tPA (Welch’s t test, n=8–11). Coronal sections of brains (from extreme left) were
acquired from vehicle, tPA, tPA plus cilostazol with no staining (location; 1 mm anterior to bregma) showing hemorrhagic spots in the infarct area (C).
34 animals were treated. Mortality rates were 0% (0/5) in saline-treated mice and 38% (5/13) in the delayed tPA group, whereas combination therapy
with tPA plus cilostazol treatments significantly reduced mortality to 6.25% (1/16) at 18 h after reperfusion (D). *P,0.05 vs. tPA (x
2 test, n=5–16).
Furthermore, combination therapy significantly prevented neurological deficits (E). *P,0.05 vs. vehicle (x
2 test, n=5–16). Data are expressed as mean
6 SEM.
doi:10.1371/journal.pone.0015178.g002
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cultures; cilostazol at 10 and 30 mM protected microvascular
endothelial cells and cilostazol at 100 mM protected pericytes, but
cilostazol at 30 or 100 mM did not protect astrocytes against cell
damage induced by tPA. Ballabh at al. have reported that
endothelial cells are directly responsible for the formation of
barriers, while astrocytes and pericytes regulate the barrier
function of endothelial cells. In addition, compared to endothelial
cells in other tissues, the BBB endothelial cells have more extensive
tight junctions [28]. As described above, the three types of cells
that comprise the BBB are different in various points. However, a
growing body of evidence indicates that tPA mediates a cerebral
ischemia-induced increase in the permeability of the neurovascular
unit. From these points of view, cilostazol may protect against cell
damage induced by tPA in endothelial cells and pericytes
comprising the neurovascular unit, presumably resulting in
improvement in the neurologic score and the survival rate.
Cilostazol increases intracellular cAMP content accordingly and
activates protein kinase A (PKA) and PI3K/Akt signaling [29].
cAMP analogs enhance the barrier function of tight junctions in
brain capillary endothelial cells [30]. cAMP-dependent induction
of claudin-5 expression could be involved in the promotion of
tight-junction function in endothelial cells [31]. Furthermore,
phosphorylation of Akt may be involved in determining cell
survival or cell death after transient focal cerebral ischemia [32].
Cilostazol induces NO production by eNOS activation via a
cAMP/PKA- and PI3K/Akt-dependent mechanism [29]. From
these points of view, we next evaluated whether cilostazol protects
Figure 3. Effects of tPA and cilostazol on acute brain injuries at 18 h after reperfusion. These figures show the effects of tPA and cilostazol
regarding hemorrhage volume (A), blood-brain barrier permeability (B), and MMP-9 expression (C) measured. Combination therapy with tPA plus
cilostazol significantly prevented this tPA-associated amplification of cerebral hemorrhage, water content, and MMP-9 activity. *P,0.05 vs. tPA
(Welch’s t test, n=7–10). Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0015178.g003
Figure 4. Effects of tPA and cilostazol on subacute brain injuries at 7 days after MCAO. These figures show the effects of tPA and
cilostazol on neurobehavioral assessment (A and B) measured at 7 days after MCAO. Combination therapy with tPA plus cilostazol increased the total
locomotor activity in the first 120 min of measurement. *P,0.05 vs. tPA (Student’s t test, n=5–7). Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0015178.g004
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demonstrated that db-cAMP prevented the cell damage induced
by tPA in human brain microvascular endothelial cells (Fig. 6A),
and this result may correlate with the result that cAMP activity
may be, in part, the mechanism under combination therapy that
protects against neuronal damage induced by tPA and prevents
hemorrhagic transformation with functional and morphological
outcomes.
The present findings indicate that cilostazol may be one of the
potential drugs to reduce hemorrhagic complications induced by
tPA. However, there are several limitations in the present study.
One limitation may be that we only examined infarct and
hemorrhagic volumes of the combination treatment at 18 h after
stroke. Namely, it remains to be rigorously determined whether
the acute neurovascular protection sustains for longer periods in
tissue recovery, and how it interfaces with tPA effects in delayed
times post-stroke. Another limitation may be whether the effect of
acute cilostazol treatment on hemorrhagic transformation induced
by MCAO was consistent with that of combination therapy of tPA
and cilostazol. Further studies may be warranted to dissect the
underlying cell signaling mechanisms of combination therapy, to
determine the optimum dosage, to test whether combined
cilostazol therapy could extend the short therapeutic window of
tPA, and to validate the possibility of a combined therapy for
future clinical application.
In conclusion, cilostazol protected against not only acute but
also subacute tPA-induced cerebral injury in the mouse that had
undergone a hemorrhagic transformation, prevented the loss of
claudin-5, and inhibited tPA-induced cell damage in human brain
microvascular endothelial cells. These effects may be due to the
Figure 5. Effects of tPA and cilostazol on endothelial cells at 18 h after reperfusion. Electron microscopic view of microvessels in a peri-
infarct area obtained from the sham model (A), the ipsilateral side of the vehicle model (B), tPA (C), and combination therapy with tPA plus cilostazol
(D) Although no significant differences were observed in the nuclei of the endothelial cells of the sham and vehicle models at 6 h, the nuclei of the
cells with tPA at 6 h significantly had disappeared. On the other hand, combination therapy with tPA plus cilostazol at 6 h significantly prevented the
exacerbation induced by tPA (E). **P,0.01 vs. tPA (x
2 test, n=11–32). Combination therapy with tPA plus cilostazol significantly decreased this tPA-
associated brain edema (F). *P,0.05 vs. tPA (Student’s t test, n=5–10). Western blot analysis measured the levels of claudin-5. tPA alone at 6 h
decreased claudin-5 levels. Combination therapy with tPA plus cilostazol prevented this tPA-associated decrease in claudin-5 (G). *P,0.05 vs. tPA
(Welch’s t test, n=3–4). Data are expressed as means 6 SEM. Ed; edema, En; endothelial cell, V; vessel. Scale bar=1 mm.
doi:10.1371/journal.pone.0015178.g005
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unit in association with cAMP activity. The present findings
indicate that a phosphodiesterase-III inhibitor (cilostazol) may be a
potential drug for reducing hemorrhagic complications induced by
tPA.
Materials and Methods
Animal Preparation
The experimental designs and all procedures were approved by
the Animal Experiment Committee of Gifu Pharmaceutical
University (permission number; 09-176, 222, 282, 308, 362, and
402). All procedures relating to animal care and treatment
conformed to animal care guidelines of this committee. All in
vivo experiments were performed using male ddY mice (4 weeks
old; body weight 22–28 g; Japan SLC Ltd., Shizuoka, Japan).
Experimental Groups and Drug Treatments
This study consisted of two different experiments. Experiment 1
aimed to investigate the evaluation of the therapeutic time window
of tPA (Grtpa, Mitsubishi Tanabe Pharma Corporation, Osaka,
Japan) at 2 h, 3 h, and 6 h after MCAO. Mice were randomly
assigned to two groups (vehicle; n=6–8, tPA; n=5–7). Experi-
ment 2 aimed to investigate the evaluation that cilostazol (Pletaal,
Otsuka Pharmaceutical Corporation, Tokushima, Japan) prevents
hemorrhagic transformation-associated damage induced by tPA at
6 h after MCAO. Mice were randomly assigned to three groups
(vehicle; n=10, tPA; n=9, tPA plus cilostazol; n=8). A dose of
10 mg/kg of tPA in 0.1 ml saline was administered intravenously
just before a reperfusion [34]. A dose of 10 mg/kg of cilostazol in
0.5% carboxymethyl cellulose was injected intraperitoneally
followed by tPA. The injection volume was adjusted to 8 ml/kg
body weight. Mice assigned to the vehicle group received an
intravenous injection of 0.1 ml saline without tPA at a timing and
volume similar to that used in the tPA group. The experiments
performed blinded for treatment group.
Focal Cerebral Ischemia
To imitate the clinical situation, we designed the present
experiment whereby tPA was administrated just before a
reperfusion by pulling out a nylon monofilament from the origin
of MCA, so that the tPA-associated damage could be assessed
under similar conditions of reperfusion [33]. Mice were anesthe-
tized with 2.0 to 2.5% isofluorane in 30% oxygen and 70% nitrous
oxide via a facemask (Soft Lander; Sin-ei Industry, Saitama,
Japan). An 8-0 nylon monofilament (Ethicon, Somerville, NJ,
USA) via the internal carotid artery, as described by Hara et al
[34], was used to induce focal cerebral ischemia. After occlusion
Figure 6. Effects of cilostazol on the tPA-stimulated human brain microvascular endothelial cells, pericytes, and astrocytes. Cell
damage after 300-mg/ml tPA treatment was assessed by measuring LDH release into the culture medium in endothelial cells (A), pericytes (B), and
astrocytes (C). The LDH level was increased by 300-mg/ml tPA treatment, and the increase was reduced by cilostazol at 30 and 100 mM in endothelial
cells, and by cilostazol at 100 mM in pericytes. In addition, db-cAMP at 300 and 1000 mM significantly prevented cell damage induced by tPA in
endothelial cells.
##P,0.05 vs. no treatment, *P,0.05, **p,0.01 vs. 300-mg/ml tPA alone (Dunnett’s test, n=4–8). Data are expressed as means 6
SEM.
doi:10.1371/journal.pone.0015178.g006
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tPA treatment [35], the nylon was gently withdrawn to restore the
blood flow in the MCA territory and the incision was closed. In all
animals during surgery, the body temperature was maintained
between 37.0 and 37.5uC with the aid of a heating lamp and
heating pad. To confirm MCAO, laser-Doppler flowmetry
(Omegaflow flo-N1; Omegawave Inc., Tokyo, Japan) measured
the regional artery blood flow (rCBF) in the MCA territory from
the temporal bone surface [12]. Mice that did not demonstrate a
significant reduction just before reperfusion (to less than 40% that
of the contralateral rCBF values) were excluded.
Tissue Processing
At 18 h after reperfusion, mice were given an overdose of
pentobarbital sodium (Dainippon Sumitomo Pharma, Osaka,
Japan) and transcardially perfused with cold saline. The mice
brains were removed immediately, and the brain was cut into 5
serial 2-mm-thick coronal block slices. In our preliminary study,
we found that, among all slices, the reproducibly largest infarct size
was in the cortical region of the left hemisphere on the anterior 4-
th slice. Therefore, we used this area to analyze the extent of
intracerebral hemorrhage, matrix metalloproteinase (MMP) -9
activity, and claudin-5 [36].
Measurement of Infarct Volume and Hemorrhagic Area
At 18 h after reperfusion, these slices were immersed for 20 min
in a 2% solution of 2, 3, 5-triphenyltetrazolium chloride (TTC)
(Sigma-Aldrich, St Louis, Mo, USA). Image J measured the
unstained areas of the total infarctions, and the infarction volume
was calculated as in a previous report [37]. These areas of the total
hemorrhagic spots as scarlet dot lesions within the area of ischemic
damage were measured using Image J, and the hemorrhagic area
was calculated.
Neurological Deficits
Mice (vehicle; n=5, tPA; n=13, tPA plus cilostazol; n=16)
were tested for neurological deficits at 24 h or 7 days after MCAO.
These were scored as described in our previous study [34].0, no
observable neurological deficits (normal); 1, failure to extend the
right forepaw (mild); 2, circling to the contralateral side
(moderate); 3, loss of walking or righting reflex (severe); 4, dead.
The investigator who rated the mice was masked as to the group to
which each mouse belonged.
Spectrophotometric Assay of Hemoglobin
Hemorrhagic transformation was quantified with a spectropho-
tometric assay of brain hemoglobin content [38]. After adding
10 ml/g saline to individual samples, they were homogenized and
followed by 30 min centrifugation (13,000 rpm). Then 200 ml
reagent (QuantiChrom Hemoglobin Assay Kit; BioAssay Systems,
Hayward, Calif, USA) was added to 50 ml supernatant. After
15 min, optical density was measured at 400 nm with a
spectrophotometer (Skan It RE for Varioskan 133 Flash 2.4;
Thermo Fisher Scientific,Waltham, MA, USA). Total hemoglobin
content was expressed as micrograms per samples (vehicle; n=9,
tPA; n=10, tPA plus cilostazol; n=7).
Measurement of Brain Water Content
At 18 h after reperfusion, the brains were divided between the
edematous area and the non-edematous area, each of which was
weighed to obtain the wet weight and then dried at 110uC for
24 h. The water content in the edematous area was calculated as
water content (%)=(wet ?weight – dry ?weight)/wet ?weight6100
[39] (vehicle; n=9, tPA; n=10, tPA plus cilostazol; n=7).
Assay of MMP-9 Activity
To measure MMP-9 activity, each sample was adjusted to the
same protein content. We followed the instructions of the
manufacturer of the MMP-9 Biotrak activity assay system kits
(R&D Systems, Minneapolis, Minn, USA) to assess MMP-9
activity in brain extracts. The total MMP-9 activity was expressed
as nanograms per samples. (vehicle; n=8, tPA; n=10, tPA plus
cilostazol; n=7).
Measurement of Locomotor Activity
Mice were individually placed in a transparent acrylic cage
(17562456125 mm) with sawdust bedding on the floor, and
digital counters with infrared sensors (NSASS01; Neuroscience,
Inc., Tokyo, Japan) measured locomotion every 10 min for
120 min. This test was performed once per animal on day 7.
[12] (tPA; n=5, tPA plus cilostazol; n=7).
Electron Microscopy
At 18 h after reperfusion, mice were anesthetized with
pentobarbital sodium and transcardially perfused with cold saline
solution followed by 2.5% glutaraldehyde in 0.1M phosphate
buffer, PH 7.4. After perfusion, the brains were removed and then
dissected. As control group, sham-operated mice were used. These
sections were cut on a Porter-Blum MT-1 ultra microtome
(DuPont-Sorvall, Wilmington Del, USA), stained with uranyl
acetate and lead salts, and examined with a JEOL 1010
transmission electron microscope (JEOL, Tokyo, Japan). More-
over, three levels of sections were selected as described above, and
five areas in the ipsilateral peri-infarct cortex in each section were
chosen. In addition, we counted the nuclei of endothelial cells
larger than 1 mm (sham; n=13, vehicle; n=13, tPA; n=29, tPA
plus cilostazol; n=41), chose some vessels and measured the area
of each brain swelling and blood vessels of the capillary artery
using Image J. We calculated the ratio of the blood vessel/brain
swelling (vehicle; n=10, tPA; n=5, tPA plus cilostazol; n=8).
Sham-operated mice were subjected to the same surgical
procedure, except that the nylon monofilament was not advanced
to occlude the MCA.
Western Blot Analysis
As control group, sham-operated mice were used. Tissues were
homogenized in 10 ml/g tissue ice-cold lysis buffer (50 mM Tris-
HCl, pH 8.0, containing 150 mM NaCl, 50 mM EDTA, 1%
Triton X-100, and protease/phosphatase inhibitor mixture). A
sample of 5 mg of protein was subjected to a 15% gradient SDS-
polyacrylamide gel electrophoresis (SuperSep Ace; Wako Pure
Chemicals, Osaka, Japan), with separated protein being trans-
ferred onto a polyvinylidene difluoride membrane (Immobilon-P;
Millipore Corporation, Billerica, MA, USA). For immunoblotting,
the following primary antibodies were used: polyclonal antibody to
claudin-5 (1:500 dilution; Zymed) and monoclonal antibody to
GAPDH (1:5000 dilution; Cell Signaling). The secondary
antibody was anti-rabbit HRP-conjugated IgG (1:5000 dilution).
The SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific, Waltham, Mass, USA) was used to
visualize the immunoreactive bands. A Lumino Imaging Analyzer
(FAS-1000; Toyobo Engineering, Osaka, Japan) and a Gel Pro
Analyzer (Media- Cybernetics, Inc., Bethesda, MD) were used to
measure the band indensity (sham; n=3, vehicle; n=4, tPA; n=3,
tPA plus cilostazol; n=3).
PDE-III Inhibitor Prevents tPA Induced Hemorrhage
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e15178Cell Cultures
Human brain microvascular endothelial cells (DS Pharma
Biomedical, Osaka, Japan) were cultured in 100-mm dishes at
37uC in HuMedia EG2 (Kurabo, Osaka, Japan) supplemented
with 2% heat-inactivated fetal bovine serum under a humidified
5% CO2 atmosphere until they reached confluency. They were
then transferred into 24-well culture plates and cultured until they
became confluent. Human brain pericytes and astrocytes (DS
Pharma Biomedical) were transferred into 24-well culture plates
and cultured in CS-C medium (DS Pharma Biomedical)
supplemented with 10% heat-inactivated fetal bovine serum until
they became confluent. The medium was discarded, and the cells
were washed twice. Then, we exposed the cells to tPA alone (10,
30, 100, and 300 mg/ml), tPA (300 mg/ml) plus cilostazol (3, 10,
30, and 100 mM) for 24 h. In addition, we exposed endothelial
cells to tPA (300 mg/ml) plus cilostazol (30 mM) plus db-cAMP
(dibutyryladenosine 3959 -cyclic monophosphate sodium salt;
Sigma-Aldrich, Madison, Wis, USA) (300 and 1000 mM) for
24 h. After the cells were treated, the conditioned medium was
harvested and used to determine the LDH kit (Promega, Madison,
Wis, USA), a marker of nonspecific cell damage.
Statistical Analysis
Data are presented as means 6 SEM. Statistical comparisons
were made using an analysis of variance followed by a Student’s t
test, Welch’s t test, Dunnett’s test, or x
2 test. P,0.05 was
considered to indicate statistical significance.
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